AR083152A1 - Formas cristalinas de inhibidores de quinasas - Google Patents

Formas cristalinas de inhibidores de quinasas

Info

Publication number
AR083152A1
AR083152A1 ARP110101990A ARP110101990A AR083152A1 AR 083152 A1 AR083152 A1 AR 083152A1 AR P110101990 A ARP110101990 A AR P110101990A AR P110101990 A ARP110101990 A AR P110101990A AR 083152 A1 AR083152 A1 AR 083152A1
Authority
AR
Argentina
Prior art keywords
crystal forms
thieno
pyrazol
pyridin
fluorophenyl
Prior art date
Application number
ARP110101990A
Other languages
English (en)
Inventor
Doug H Hoffman
Jonathan Miller
Geoff G Z Zhang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR083152A1 publication Critical patent/AR083152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sales citrato de N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea y formas cristalinas de las mismas, que son ingredientes farmacéuticos apropiados para hacer composiciones farmacéuticas útiles para el tratamiento de enfermedades, por ejemplo cáncer.Reivindicación 2: El compuesto citrato diácido de N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea en una forma cristalina sólida, caracterizado porque la forma cristalina es la Forma I, caracterizada por lo menos por un pico de difracción de rayos X en polvo en una o más cualesquiera de las siguientes posiciones: 11,80, 14,59, 15,95, 21,38, 26,12º 2q, ± 0,2º 2q.
ARP110101990A 2010-06-09 2011-06-09 Formas cristalinas de inhibidores de quinasas AR083152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35303810P 2010-06-09 2010-06-09

Publications (1)

Publication Number Publication Date
AR083152A1 true AR083152A1 (es) 2013-02-06

Family

ID=44454811

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101990A AR083152A1 (es) 2010-06-09 2011-06-09 Formas cristalinas de inhibidores de quinasas

Country Status (18)

Country Link
US (2) US8633217B2 (es)
EP (1) EP2580220B1 (es)
JP (1) JP5727598B2 (es)
KR (1) KR20130112856A (es)
CN (1) CN103038239A (es)
AR (1) AR083152A1 (es)
AU (1) AU2011264902B2 (es)
BR (1) BR112012031485A2 (es)
CA (1) CA2802029A1 (es)
ES (1) ES2536503T3 (es)
HK (1) HK1179255A1 (es)
MX (1) MX2012014348A (es)
NZ (1) NZ604649A (es)
RU (1) RU2012157469A (es)
SG (2) SG186250A1 (es)
TW (1) TWI482770B (es)
WO (1) WO2011156464A1 (es)
ZA (1) ZA201209648B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170197980A1 (en) * 2014-06-25 2017-07-13 Abbvie Inc. N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
US20070135387A1 (en) * 2005-12-08 2007-06-14 Michaelides Michael R Inhibitors of protein kinases
TWI438205B (zh) * 2008-03-05 2014-05-21 Methylgene Inc 蛋白質酪胺酸激酶活性抑制劑
WO2010065825A2 (en) 2008-12-05 2010-06-10 Abbott Laboratories Kinase inhibitors with improved cyp safety profile

Also Published As

Publication number Publication date
JP5727598B2 (ja) 2015-06-03
US8940759B2 (en) 2015-01-27
JP2013528221A (ja) 2013-07-08
US20140296284A1 (en) 2014-10-02
ES2536503T3 (es) 2015-05-26
EP2580220A1 (en) 2013-04-17
TW201202235A (en) 2012-01-16
TWI482770B (zh) 2015-05-01
ZA201209648B (en) 2013-08-28
MX2012014348A (es) 2013-04-24
US8633217B2 (en) 2014-01-21
AU2011264902B2 (en) 2015-01-29
US20120202844A1 (en) 2012-08-09
NZ604649A (en) 2014-11-28
WO2011156464A8 (en) 2012-10-11
KR20130112856A (ko) 2013-10-14
CN103038239A (zh) 2013-04-10
HK1179255A1 (en) 2013-09-27
BR112012031485A2 (pt) 2016-11-01
RU2012157469A (ru) 2014-07-20
SG2014014278A (en) 2014-06-27
EP2580220B1 (en) 2015-02-11
AU2011264902A1 (en) 2013-01-10
WO2011156464A1 (en) 2011-12-15
CA2802029A1 (en) 2011-12-15
SG186250A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
AR096758A1 (es) Inhibidores cristalinos de bromodominios
PH12014501277A1 (en) Kinase inhibitors
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
NZ593295A (en) Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor
ATE482961T1 (de) Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung
CR20140216A (es) 5,7-imidazo[1,2-c]pirimidinas sustituidas
EA201100030A1 (ru) Пиразольные соединения 436
WO2012004706A3 (en) Chemical compounds
UY31068A1 (es) Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
PH12014501278A1 (en) Kinase inhibitors
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
MX2012014386A (es) Formas cristalinas de inhibidores de cinasa.
MX340033B (es) Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
AR090209A1 (es) Polimorfos de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea y composiciones farmaceuticas que los comprenden
AR083152A1 (es) Formas cristalinas de inhibidores de quinasas
AR083722A1 (es) Formas cristalinas de inhibidores de quinasas
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
MX2022004806A (es) Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763).

Legal Events

Date Code Title Description
FB Suspension of granting procedure